CD38 and acute myeloid leukemia: Monoclonal antibodies treatments include naked antibodies against AML surface antigens such as CD33 (e.g. lintuzumab) or CD38 (e.g. daratumumab), antibodies conjugated to toxins in various anti-CD33 (gemtuzumab ozogamicin, SGN33A, IMGN779) and anti-CD123 (IMGN632, SL-401, SGN-CD123A) formulations, antibodies conjugated to radioactive particles such as Iodine or Actinium-labeled anti-CD33 or anti-CD45 antibodies, and multiple bispecific antibodies (Table 1).